Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Sep 16;10:15171. doi: 10.1038/s41598-020-71519-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

VISTA blockade with SG7 slows tumor growth in multiple syngeneic mouse models. (a) B16F10 tumor-bearing C57BL/6 mice were treated with 10 mg/kg SG7 (dead Fc; mIgG2a-LALA/PG) bi-weekly, starting on day 10 (red arrows). n = 5 mice per group; mean tumor volume of each group (left) and individual tumor growth curves (right). All mice were euthanized on Day 21 due to volume and ulceration of untreated tumors. These data are representative of two independent experiments. Mean + SEM are shown. (b) MC38 tumor-bearing C57BL/6 mice were treated with 30 mg/kg SG7 (dead Fc) and/or 5 mg/kg anti-PD1, starting on day 9 (black arrows); n = 7 mice per group; mean tumor volume of each group (left) and individual tumor growth curves (right); all mice were euthanized on Day 17 due to volume and ulceration of untreated tumors. These data are representative of two independent experiments. Mean + SEM are shown. (c) 4T1 tumor-bearing BALB/c mice were treated with 30 mg/kg SG7 (active Fc; mIgG2a) or 30 mg/kg SG7 (dead Fc) bi-weekly, starting on day 8 (black arrows). n = 5–7 mice per group as indicated. All mice were euthanized on Day 17 for tumor extraction. Mean + SEM are shown. P-values in a–c calculated by repeated measures two-way ANOVA (Tukey’s), asterisks denote significant difference from PBS (untreated), *p < 0.05, **p < 0.005, (d) Immune flow analysis of extracted 4T1 tumors on Day 17. The percentage of PMN-MDSCs, CD4 ⁺ T cells and CD8 ⁺ T cells out of total CD45⁺ cells in each tumor sample are shown. Mean ± SEM are shown. P-values calculated by one-way ANOVA (DMCT), *p < 0.05, **p < 0.005.